You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
智飛生物(300122.SZ):擬增資取得宸安生物51%股權
格隆匯 03-21 18:58

格隆匯3月21日丨智飛生物(300122.SZ)公佈,智飛生物與宸安生物、智睿投資、張高峽簽署了《關於重慶宸安生物製藥有限公司之增資擴股協議》。公司將以現金向宸安生物增資人民幣59,326.5306萬元,取得宸安生物51%的股權。本次增資定價以具有證券期貨業務資格的資產評估機構出具的《評估報吿》中的評估結果作為定價依據,協商確定本次增資前宸安生物100%股權價值為57,000.00萬元,相應確定本次現金增資取得51%股權的總增資金額為人民幣59,326.5306萬元。本次增資完成後,宸安生物將成為公司的控股子公司。

宸安生物聚焦糖尿病、肥胖等代謝類疾病領域的適應症。代謝類疾病通常具有慢性、不可逆的病理特徵,其治療往往需要長期甚至終身藥物干預以控制病情進展並預防併發症,是關係人民長期健康的重大疾病領域。宸安生物的司美格魯肽注射液(降糖)已完成臨牀III期試驗、司美格魯肽注射液(減重)已完成臨牀III期患者入組,已佈局兼具GLP-1多品種以及胰島素藥物圖譜。同時,宸安生物重組蛋白底層技術的十年積澱,以及上市公司專業、規模化的市場推廣團隊,有望促進宸安生物在競爭中佔據有利地位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account